Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Preventing heart failure

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Heart failure is rarely a first event. It is the end of a road that usually starts with blood pressure, cholesterol, diabetes or a heart attack, and that road takes decades.

That makes it one of the more preventable serious conditions, and guidelines now formally name the stages before any symptoms exist so they can be treated.

Related pages: Heart failure

The bottom line

What we know
  • High blood pressure is the most modifiable cause.
  • Intensive blood pressure lowering reduced heart failure substantially in trial data.
  • Preventing and treating coronary disease prevents the heart failure that follows it.
  • SGLT2 inhibitors reduce heart failure in people with diabetes.
  • Alcohol, obesity and sleep apnea are modifiable contributors.
What is still open
  • The optimal blood pressure target for heart failure prevention specifically.
  • How much of HFpEF is preventable through weight.
  • Who should receive echocardiographic screening.

The story, step by step

  1. 1. The stages before symptoms ()
  2. 2. Blood pressure ()
  3. 3. The coronary route ()
  4. 4. Diabetes and weight ()
  5. 5. Toxins and exposures ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Stage A and stage B

Review of many studies

What happens

Where prevention happens.

What the research shows

  • Stage A is being at risk, with high blood pressure, diabetes, obesity, coronary disease, a family history of cardiomyopathy or exposure to cardiotoxic drugs, but no structural heart change.
  • Stage B is structural change without symptoms: a previous heart attack, a thickened or enlarged ventricle, reduced ejection fraction, or valve disease, with no breathlessness or swelling.
  • Stage B is common and almost entirely unrecognised, because without symptoms nobody looks.
  • A raised natriuretic peptide in someone at risk identifies people who benefit from closer assessment, and screening with it followed by intervention reduced new heart failure in a trial.
  • Treating stage B with ACE inhibitors or ARBs and beta blockers, where indicated, reduces progression to symptomatic heart failure.
  • Most people diagnosed with heart failure spent years in stage A or B first.

Why it matters

Naming these stages matters because it makes prevention a clinical task with specific actions rather than general advice about healthy living.

What's still uncertain

  • Who should be screened with natriuretic peptides.
  • How widely echocardiographic screening is justified.

Read more

Next: Blood pressure

Part 2 of 5

The biggest lever

Review of many studies

What happens

Decades of afterload.

What the research shows

  • High blood pressure forces the left ventricle to pump against resistance, which makes it thicken and stiffen, the route into HFpEF.
  • It also drives coronary disease and heart attack, the route into HFrEF.
  • In the SPRINT trial, targeting a systolic pressure below 120 rather than below 140 reduced heart failure substantially, along with other cardiovascular events.
  • Heart failure is among the cardiovascular outcomes most responsive to blood pressure lowering.
  • Sodium reduction, weight management, activity, limiting alcohol and treating sleep apnea all contribute alongside medicines.
  • Home blood pressure monitoring, done properly, predicts outcomes better than clinic readings.

Why it matters

If one intervention prevented more heart failure than any other, it would be treating blood pressure properly in middle age.

What's still uncertain

  • The optimal target for heart failure prevention specifically.
  • How to improve long-term control at population level.

Read more

Next: The coronary route

Part 3 of 5

Preventing the heart attack

Review of many studies

What happens

Dead muscle is permanent.

What the research shows

  • Coronary artery disease is the leading cause of heart failure, mostly through heart attacks that destroy muscle.
  • Statins and other lipid-lowering treatment reduce heart attacks, and so reduce the heart failure that follows them.
  • Stopping smoking is the single largest modifiable cardiovascular intervention available, with benefit starting within months.
  • Prompt treatment of a heart attack, with faster reperfusion, limits the amount of muscle lost and the resulting remodelling.
  • After a heart attack, ACE inhibitors and beta blockers reduce remodelling and prevent progression to heart failure.
  • Recognising heart attack symptoms and calling 911 rather than waiting is part of heart failure prevention, because time is muscle.

Why it matters

Heart failure prevention and heart attack prevention are mostly the same programme, which makes the case for treating risk factors stronger than either alone.

What's still uncertain

  • How much earlier reperfusion reduces later heart failure.
  • Optimal post-infarction treatment duration.

Read more

Next: Diabetes and weight

Part 4 of 5

The metabolic route

Review of many studies

What happens

And a drug that prevents it.

What the research shows

  • Diabetes damages heart muscle directly and accelerates coronary disease, roughly doubling heart failure risk.
  • SGLT2 inhibitors reduce heart failure hospitalisation in people with type 2 diabetes, which was first noticed as an unexpected finding in cardiovascular safety trials.
  • Obesity raises risk through blood pressure, diabetes, blood volume, inflammation and sleep apnea, and is particularly associated with HFpEF.
  • Weight loss improves symptoms and exercise capacity in obesity-related HFpEF, and GLP-1 medicines have shown benefit in trials.
  • Untreated obstructive sleep apnea raises blood pressure and strains the heart, and is common and under-diagnosed.
  • Regular activity, at least 150 minutes a week of moderate exercise, independently lowers risk.

Why it matters

The metabolic route into heart failure now has specific preventive drugs, which was not true a decade ago.

What's still uncertain

  • How much of HFpEF is preventable through weight management.
  • Whether treating sleep apnea reduces heart failure incidence.

Read more

Next: Toxins and exposures

Part 5 of 5

Alcohol, drugs and treatment

Review of many studies

What happens

Avoidable damage.

What the research shows

  • Sustained heavy drinking directly weakens heart muscle, and reducing or stopping produces substantial recovery in many people.
  • Stimulant drugs including cocaine and methamphetamine cause cardiomyopathy, often in younger people.
  • Anthracycline chemotherapy and some targeted cancer drugs damage heart muscle, and chest radiotherapy can damage muscle, valves and coronary arteries years later.
  • Cardio-oncology services now monitor heart function during and after cancer treatment, and preventive cardiac medicines are used in higher-risk patients.
  • Anyone who has had anthracycline chemotherapy or chest radiotherapy should make sure later clinicians know, because the risk persists for decades.
  • Iron overload, from haemochromatosis or repeated transfusion, damages the heart and is treatable.

Why it matters

The cancer survivor group is growing and is frequently not followed up for cardiac risk, despite the exposure being documented in their own records.

What's still uncertain

  • Optimal cardiac monitoring schedules after cancer treatment.
  • Which preventive cardiac drugs help during chemotherapy.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.